<DOC>
	<DOCNO>NCT00788333</DOCNO>
	<brief_summary>This Phase I/II study evaluate safety profile , tolerability , pharmacokinetics pharmacodynamics follow daily oral dos 50 200 mg BMS-754807 combination trastuzumab ( Herceptin® ) subject advanced metastatic Her-2-positive breast cancer . In addition , study expect identify recommend dose dose range BMS-754807 combination trastuzumab Phase II study provide preliminary evidence anti-tumor activity Her-2-positive breast cancer subject trastuzumab failure</brief_summary>
	<brief_title>Combination Study BMS-754807 Herceptin® Patients With Advanced Metastatic Her-2-positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>For additional information trial , please call ( 910 ) 5582913 Subjects locally advanced metastatic Her2positive breast cancer fail least one trastuzumab contain regimen . Prior treatment Her2targeted agent ( e.g . lapatinib , pertuzumab , trastuzumab DM1 etc . ) allow Histologic cytologic diagnosis Her2positive breast cancer ECOG status 0 1 Symptomatic brain metastasis Any condition require chronic use steroid Any disorder dysregulation glucose homeostasis ( history Type 1 2 Diabetes Mellitus prediabetic symptom History glucose intolerance Women childbearing potential unwilling unable use acceptable contraception method</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Advanced Metastatic Her-2-positive Breast Cancer</keyword>
</DOC>